Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Dobbelstein

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Virus Research|April 11, 2003
Viruses in therapy--royal road or dead end?Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|December 21, 2012
Interchanging heads: p53 re-composes the DREAM/MMB complex to repress transcriptionMatthias Dobbelstein
Journal of Virology|June 29, 2004
E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infectionUrs Hobom, Matthias Dobbelstein
Cancer Research|November 3, 2006
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapyDominique Kranz, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|May 12, 2011
Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exonUlrike Beyer, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|January 26, 2006
Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNAMichael Schümann, Matthias Dobbelstein
Cancer Research|February 3, 2006
Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progenyMichael Schümann, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|May 25, 2012
A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapyDominique Kranz, Matthias Dobbelstein
Nature Reviews. Drug Discovery|March 1, 2014
Targeting tumour-supportive cellular machineries in anticancer drug developmentMatthias Dobbelstein, Ute Moll
Cell Cycle (Georgetown, Tex.)|July 16, 2004
p73 and p63: why do we still need them?Giovanni Blandino, Matthias Dobbelstein
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Virus Research|April 11, 2003
Viruses in therapy--royal road or dead end?Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|December 21, 2012
Interchanging heads: p53 re-composes the DREAM/MMB complex to repress transcriptionMatthias Dobbelstein
Journal of Virology|June 29, 2004
E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infectionUrs Hobom, Matthias Dobbelstein
Cancer Research|November 3, 2006
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapyDominique Kranz, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|May 12, 2011
Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exonUlrike Beyer, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|January 26, 2006
Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNAMichael Schümann, Matthias Dobbelstein
Cancer Research|February 3, 2006
Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progenyMichael Schümann, Matthias Dobbelstein
Cell Cycle (Georgetown, Tex.)|May 25, 2012
A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapyDominique Kranz, Matthias Dobbelstein
Nature Reviews. Drug Discovery|March 1, 2014
Targeting tumour-supportive cellular machineries in anticancer drug developmentMatthias Dobbelstein, Ute Moll
Cell Cycle (Georgetown, Tex.)|July 16, 2004
p73 and p63: why do we still need them?Giovanni Blandino, Matthias Dobbelstein
Pageof 11